Adachi Hayamitsu, Nakae Koichi, Sakamoto Shuichi, Nosaka Chisato, Atsumi Sonoko, Shibuya Masabumi, Higashi Nobuaki, Nakajima Motowo, Irimura Tatsuro, Nishimura Yoshio
Institute of Microbial Chemistry (BIKAKEN), Numazu Branch, Shizuoka, Japan.
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
J Antibiot (Tokyo). 2017 Nov 1. doi: 10.1038/ja.2017.138.
Microbial metabolites have attracted increasing interest as a source of therapeutics and as probes for biological mechanisms. New microbial metabolites and derivatives targeted at inflammation and bone disease therapy have been identified by focusing on prostaglandin release, osteoblast differentiation and immune cell functions. These modulators of inflammatory processes and bone disease contribute to our understanding of biological mechanisms and support identification of the therapeutic potential of drug lead candidates. The present review describes recent advances in the chemistry and analysis of inhibitors of prostaglandin release or other functional molecules of immune cells, as well as inducers of osteoblast differentiation, including biological and pharmacological activities.The Journal of Antibiotics advance online publication, 1 November 2017; doi:10.1038/ja.2017.138.
微生物代谢产物作为治疗药物的来源和生物学机制的探针,已引起越来越多的关注。通过关注前列腺素释放、成骨细胞分化和免疫细胞功能,已鉴定出针对炎症和骨疾病治疗的新型微生物代谢产物及其衍生物。这些炎症过程和骨疾病的调节剂有助于我们理解生物学机制,并支持对药物先导候选物治疗潜力的鉴定。本综述描述了前列腺素释放抑制剂或免疫细胞其他功能分子以及成骨细胞分化诱导剂在化学和分析方面的最新进展,包括生物学和药理活性。《抗生素杂志》于2017年11月1日在线优先发表;doi:10.1038/ja.2017.138 。